(KYTX) Kyverna Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 519m USD | Total Return: 251% in 12m
Avg Turnover: 7.79M
Warnings
Share dilution 39.8% YoY
Interest Coverage Ratio -139.2 is critical
Altman Z'' -12.51 < 1.0 - financial distress zone
Volatile Below Avwap Earnings
Tailwinds
Leader
Kyverna Therapeutics (KYTX) is a clinical-stage biotechnology firm specialized in engineering cell therapies for autoimmune conditions. Its primary focus is the development of KYV-101, an autologous CD19 CAR T-cell therapy currently being evaluated for neurological and systemic autoimmune disorders such as myasthenia gravis and stiff person syndrome.
The company utilizes a business model centered on chimeric antigen receptor (CAR) T-cell technology, a modality traditionally used in oncology that is now being pivoted toward immunology to reset the immune system. Kyverna maintains a strategic collaboration with Intellia Therapeutics to integrate CRISPR-based gene editing into its allogeneic, or off-the-shelf, product pipeline.
The biotechnology sector often faces high capital expenditures and rigorous regulatory hurdles during late-stage clinical trials. Investors can utilize ValueRay to further analyze the companys financial health and clinical milestones. Headquartered in Emeryville, California, the firm continues to expand its portfolio through both autologous and allogeneic manufacturing platforms.
- Clinical trial data readouts for KYV-101 determine long-term asset valuation
- FDA regulatory approval timelines for CD19 CAR T-cell autoimmune therapies
- Research collaboration milestones and funding from Intellia Therapeutics partnership
- Cash runway and burn rate management for late-stage clinical development
- Scaling manufacturing capabilities for autologous and allogeneic cell therapy pipelines
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.59 > 0.02 and ΔFCF/TA -6.84 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.59 > 3% & CFO -150.4m > Net Income -156.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.4m) vs 12m ago 39.84% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.78%; Δ -0.78% > 0%) |
| Interest Coverage Ratio: -139.2 > 6 (EBITDA TTM -155.9m / Interest Expense TTM 1.13m) |
| A: 0.83 (Total Current Assets 241.7m - Total Current Liabilities 29.7m) / Total Assets 257.0m |
| B: -1.81 (Retained Earnings -464.6m / Total Assets 257.0m) |
| C: -0.61 (EBIT TTM -157.6m / Avg Total Assets 258.8m) |
| D: -7.56 (Book Value of Equity -464.6m / Total Liabilities 61.4m) |
| Altman-Z'' = -12.51 = D |
As of May 24, 2026, the stock is trading at USD 8.90 with a total of 811,157 shares traded.
Over the past week, the price has changed by -8.64%,
over one month by -15.25%,
over three months by +9.61% and
over the past year by +251.01%.
Kyverna Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy KYTX.
- StrongBuy: 3
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 30.4 | 241.6% |
P/B = 2.6546
Revenue TTM = 0.0 USD
EBIT TTM = -157.6m USD
EBITDA TTM = -155.9m USD
Long Term Debt = 24.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.99m USD (from shortTermDebt, last quarter)
Debt = 31.0m USD (corrected: LT Debt 24.7m + ST Debt 1.99m) + Leases 4.29m
Net Debt = -205.4m USD (calculated: Debt 31.0m - CCE 236.4m)
Enterprise Value = 313.8m USD (519.2m + Debt 31.0m - CCE 236.4m)
Interest Coverage Ratio = -139.2 (Ebit TTM -157.6m / Interest Expense TTM 1.13m)
EV/FCF = -2.08x (Enterprise Value 313.8m / FCF TTM -151.0m)
FCF Yield = -48.12% (FCF TTM -151.0m / Enterprise Value 313.8m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.65m) / Revenue TTM)
Tobins Q-Ratio = 1.22 (Enterprise Value 313.8m / Total Assets 257.0m)
Interest Expense / Debt = 3.65% (Interest Expense 1.13m / Debt 31.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -124.5m (EBIT -157.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.15 (Total Current Assets 241.7m / Total Current Liabilities 29.7m)
Debt / Equity = 0.16 (Debt 31.0m / totalStockholderEquity, last quarter 195.6m)
Debt / EBITDA = 1.32 (negative EBITDA) (Net Debt -205.4m / EBITDA -155.9m)
Debt / FCF = 1.36 (negative FCF - burning cash) (Net Debt -205.4m / FCF TTM -151.0m)
Total Stockholder Equity = 191.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -60.42% (Net Income -156.4m / Total Assets 257.0m)
RoE = -23.86% (Net Income TTM -156.4m / Total Stockholder Equity 655.6m)
RoCE = -23.16% (EBIT -157.6m / Capital Employed (Equity 655.6m + L.T.Debt 24.7m))
RoIC = -54.28% (negative operating profit) (NOPAT -124.5m / Invested Capital 229.3m)
WACC = 12.97% (E(519.2m)/V(550.2m) * Re(13.57%) + D(31.0m)/V(550.2m) * Rd(3.65%) * (1-Tc(0.21)))
Discount Rate = 13.57% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.56 | Cagr: 16.19%
[DCF] Fair Price = unknown (Cash Flow -151.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.01 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.68 | Chg30d=+8.67% | Revisions=+25% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.74 | Chg30d=-2.29% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=-2.88 | Chg30d=+1.62% | Revisions=+0% | GrowthEPS=+21.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.95 | Chg30d=-3.70% | Revisions=+0% | GrowthEPS=-2.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +25%